Mitsubishi Tanabe Pharma America Announces Presentations at XXVIII World Congress on Parkinson's Disease and Related Disorders
Jersey Desk/10224869

JERSEY CITY, N.J., May 12, 2023 ~ Mitsubishi Tanabe Pharma America, Inc. (MTPA) announced today that two presentations on their investigational ND0612 in Parkinson's disease (PD) will be shared at the International Association of Parkinsonism and Related Disorders (IAPRD) XXVIII World Congress on Parkinson's Disease and Related Disorders, being held in Chicago, Ill., May 13-16.

Gustavo A. Suarez Zambrano, M.D., Vice President of Medical Affairs at MTPA expressed his excitement for the opportunity to share further research from their ongoing Phase 2b and Phase 3 studies investigating ND0612 as a potential treatment option for people with PD experiencing motor fluctuations. He added that these presentations focus on growing understanding of the role ND0612 may play in PD, supporting their determination to research and explore treatment options for people living with this disease.

MTPA's posters will be on exhibition at the meeting on May 14, 8:00 a.m. – 4:30 p.m. CDT and May 15, 10:30 a.m. – 4:15 p.m. CDT which will include findings from two ongoing studies evaluating investigational ND0612 in people with PD with motor fluctuations including details on enrollment characteristics of randomized study participants in the Phase 3 BouNDless study evaluating data on the efficacy, safety and tolerability of ND0612, and patient-reported quality of life outcomes from an exploratory analysis of the Phase 2b BeyoND study evaluating long-term safety with ND0612 which are being conducted by NeuroDerm Ltd., a wholly owned subsidiary of Mitsubishi Tanabe Pharma Corporation (MTPC), MTPA's parent company.

More on Jersey Desk
The first poster presentation will be by Joaquim J. Ferreira from University of Lisbon which will focus on enrollment characteristics for patients entering a Phase 3 study of subcutaneous levodopa/carbidopa infusion with ND0612 while the second poster presentation by Stuart H Isaacson M D from Parkinson's Disease and Movement Disorders Center of Boca Raton will focus on quality of life with continuous subcutaneous levodopa/carbidopa infusion: Exploratory findings from the ND0612 BeyoND study .

Mitsubishi Tanabe Pharma America is hopeful that these presentations will help to further understand the role that ND0612 may play in treating PD and provide more treatment options for those living with this disease
Filed Under: Business

Show All News | Report Violation


Latest on Jersey Desk